EFFICACY OF CEM-THERAPY Selection of publications for the ...
Upcoming SlideShare
Loading in...5

Like this? Share it with your network

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads


Total Views
On Slideshare
From Embeds
Number of Embeds



Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

    No notes for slide


  • 1. EFFICACY OF CEM-THERAPY Selection of publications for the clinical test review The publications, describing the terminated prospective controlled tests of the EHF-therapy (extreme high frequency) at the different diseases, in which the patient groups were selected by the randomization or minimization methods and compared according to the age, sex, gravity and duration of disease, a presence of attendant diseases and the investigation results were adequately statistically treated, are included into review. The clinical investigations, made on more than 8000 patients and healthy volunteers in the large medical centers of Moscow, Tomsk, Saratov, Nizhny Novgorod and etc., were meeting the selection criteria.
  • 2. Treatment The EHF-therapy effectiveness in the modes analogous to the CEM-TECH apparatus modes was assessed (noise, BRR-background resonance radiation). The EHF-therapy was isolated or at the background of a standard therapy compared to a standard therapy. The EHF-range EMR (electromagnetic radiation) effected the affected organ projections or a pathologic focus and/or the biologically active points (BAP) and zones. There was no the EHF-therapy in the control groups or there was the EHF-effect imitation, i.e. a blind placebo control.
  • 3. Spine pain syndrome Totally, 407 patients at the age of 19-83 years with the vertebral osteochondrosis neurologic manifestations were examined and treated. Thus, an expressed anesthetic effect of the EHF-therapy at the vertebral osteochondrosis neurologic manifestations is established. p<0,05
  • 4. Cerebrovascular pathology A headache, vertigo, the arterial pressure (AP) fluctuation were abruptly eased after the EHF session in the basic group patients with an asthenic disorder. The AP was stabilized in more than 75% of patients on the 5-6 procedure (in a control group – on the 10-12 day), a headache was less intensive rapidly disappearing. The asthenic manifestations were smoothly vanishing. p<0,05
  • 5. Trigeminal neuralgia Megdiatov et al. were reporting of the EHF effective use in patients with the trigeminal neuralgia . A reduced pain intensity and a decreased incidence of the neuralgia attacks were noted in 19 of 27 patients from a group 2 (an actual EHF) compared to 4 of 25 patients from a control group, receiving a sham EHF procedure. p<0,01
  • 6. Syndrome of vegetative dystonia p<0,0001 503 patients at the age of 5-63 years with a vegetative dystonia syndrome were examined and treated. Since the 3-4 day of treatment the fatigability, irritability, emotional liability, a sleep disturbance, headaches have been decreasing or disappearing at the EHF-therapy use. A working capacity and mood have been increasing.
  • 7. Traumatic and postoperative pain syndrome p<0,05 All investigators have noted an expressed anesthetic effect of the EHF-therapy. The pain decrease in a postoperative wound was in 3-12 hours after the first session, a full disappearance of pains was beginning in the proximate 2 days. The EHF-therapy use was leading to a promedol dose three times decrease for the postoperative pain cupping. The pains in wound have been aching for 3-5 days in the control group patients.
  • 8. Joint diseases p<0,05 Totally, 500 patients at the age of 25-79 years with the degenerative and dystrophic diseases of joints were examined and treated.
  • 9. Before therapy After CEM-Tech device therapy arthritis
  • 10. Stomach and duodenal u lcer p<0,001 Totally, 913 patients with an ulcerous disease of the stomach and duodenum were examined and treated. The ulcerous defect epithelization dates were assessed. An inclusion of the EHF-therapy into a medical complex leads to the epithelization date reduction by 2-4 days, in the average (14-16 days versus 18-20 days in a control group).
  • 11. Psoriasis p<0,05 Totally, 336 patients at the age of 14-72 years with psoriasis were examined and treated (the extended psoriasis – in 76 humans, a psoriatic arthritis – in 58 humans). All investigators were noting the anti-inflammatory, analgetic, regenerative effect, a resorption of infiltrates at the EHF-therapy inclusion into a medical complex.
  • 12. Ischemic heart disease – antianginal effect p<0,001 Totally, 616 patients at the age of 41-69 years with the ischemic heart disease (IHD) were examined and treated.
  • 13. The EHF-therapy in acute period in patients with a myocardial infarction Good clinical effect p<0,01 Satisfactory clinical effect p<0,05
  • 14. Prostatitis Figure 1 Figure 2 Thereby, high effectiveness of EHF-therapy in bioresonance regime during chronic prostatitis was shown. EHF-therapy has expressed anesthetic action, it eliminates inflammatory occurrences, improves functional activity of prostate gland, leads to correction of immunologic disturbances and sexual function stimulation.
  • 15. Intestine cancer – wound healing p<0,01
  • 16.
    • Modern indications to the EHF-therapy use in oncology in the following form:
    • Preparation of patients with the basic localization cancer to the combined treatment stages (preparation of the organs and systems to a surgical trauma, radial damages and a medicinal aggression).
    • Treatment of the attendant diseases and a prophylaxis of complications in humans from the risk groups.
    • Prophylaxis and elimination of complications after the special methods of treatment.
    • Treatment of a paraneoplastic syndrome.
    • Increase of the other treatment method results.
    • Symptomatic therapy of the incurable patients.
    • Systemic correlation of the ecologic and precancerous pathology.
    • Prophylaxis of a tumor process progress after a combined treatment.
  • 17.
    • Analysis of the publications about clinical tests let us make conclusions that EHF influence on the organism allow to:
    • reduce pain of any genesis and inflammations in pathologic spots;
    • reduce rehabilitation treatment period of the wide spectrum of diseases;
    • increase the potential of rehabilitation treatment in the outpatient and home setting;
    • perform primary and secondary prophylactics;
    • rise the efficiency of medicaments use, and at the same time low the dose of prescribed medicine, and in some cases refuse from medicaments appliance.
  • 18.
    • All scientific efforts confirmed good tolerance of human body to EHF influence, and the absence of complications and side effects. The same can be applied to long-term observation of recovering patients (1-2 years), the absence or insignificant perception in the point of influence was observed (some patients had a perception of “light tingling” and “goose skin”).
  • 19.
    • There are no any revealed serious contraindications for its use, however one should avoid its prescription in the following cases:
    • unstated diagnose;
    • individual intolerance of this type of therapy
    • pregnancy
    • driving and other work connected with danger and concentration (management of mechanisms and so forth).
    • In the table below there are nosologic forms and registered basic effects of EHF-therapy;
    • cardio stimulator.
  • 20.
    • In the following table you can see nosologic forms and the main registered effects of EHF therapy:
  • 21. Neuropathology Disappearance of asthenic manifestations, emotional instability, hypertension, headache, vertigo, blood pressure fluctuation, night sleep restoration 4. Brain exogeno-organic affections (traumatic, vascular, infectious-toxic and complex genesis) Disappearance or substantial decrease in headache and vertigo, blood pressure normalization 3. Vertebrobazilare deficiency Evident anesthetic effect, increase in tolerance to physical activity, increase in spine excursion 2. Spine silicosis in children Evident anesthetic effect, increase in pain threshold in local alogenic zones 1. Naturopathic manifestations of spine osteochondrosis, including discogenic radiculopathy
  • 22. Neuropathology Decrease in muscular tone, increase in the range of active motions 10. C erebral spastic infantile paralysis Decrease or disappearance of irritability, emotional instability, sleep disturbances, increase in efficiency, mood increase 9. Reactive neurosis and stress reactions – treatment and prevention Vegetative status normalization, decrease or disappearance of headaches, improvement of geodynamics on the basis of rheography data 8. Vegetative distony syndrome, including vegetative crisis (panic attack) Analgetic effect, the speed increase of impulse conduction on nerves 7. Mono- and poly-neuropathy Significant decrease of intensity of headache and duration of attacks 6. Headache Cerebral blood flow normalization, lipidic metabolism indicators normalization 5. Cerebral atherosclerosis
  • 23. Joint diseases Significant decrease in pain and morning joint stiffness, immunomodulatory effect 13. Atrophic arthritis Analgetic effect, hemostasis normalization 12. Hemarthrosis and hemophilic artropathy Anti-inflammatory effect, increase in muscle strength, range of motions in interested joint and tolerance to physical activity 11. Degenerative dystrophic joint diseases (deforming osteoarthritis, Perthers’ disease, psoriatic osteoarthropathy )
  • 24. Surgical pathology Shortening of inflammation exudative phase period and stimulation of the earlier start of reparative processes, normalization of cytomorphologic leukocyte characteristics 16. Posttraumatic osteomyelitis Analgetic effect, fast formation of granulation tissue and epithelization 15. Burns Shortening of all phases of wound process, anti-inflammatory action, regeneration stimulation, suppuration prophylactics, evident analgetic effect, decrease in the dose of analgetic medications 14. Traumatic and postsurgical skin injuries of bone and soft tissues, including complicated with suppurative inflammation and sluggish wounds
  • 25. Surgical pathology Shortening of the treatment period, positive influence on the condition of immune system 19. Acute pancreatitis Anti-inflammatory action 18. A cute cholecystitis Analgetic effect, normalization of microcirculation and trophic disturbances, restoration of normal range of motions 17. Posttraumatic stiffness
  • 26. Gastroenterology Effective pain reduction, restoration of pancreas functions 23. Chronic pancreatitis Faster and more effective pain and dyspepsia syndromes reduction 22. Chronic gastroduodenitis, including the one with presence of Helicobacter pilori infection Faster and more effective pain and dyspepsia syndromes reduction, decrease in signs of thickening and crystallization of bile, normalization of gallbladder contractile function 21. Incompetence of bile-excreting tracts Shortening of epithelization period of ulcer effect , decrease in the amount of recurrences 20. Gastric ulcer and duodenal ulcer disease, including complicated with bleeding and perforation or penetration
  • 27. Obstetrics and gynecology immunomodeling effect, reduction of inflammatory complications 27. Postabortal complications Growth of luteal phase term of menstrual cycle, rise of oestradiol and progesterone levels, cancel of need in hormonotherapy 26. Miscarriage of pregnancy anesthetic effect, commissural structures softening, restoration of reproductive function 25. Chronic adnexitis, including cases with reproductive function disorder
  • 28. Dermatology Skin itch decrease 30. Neurodermatitis Faster recovery 29. Acne Faster recovery 28. Microbial eczema Anti-allergenic effect, itch termination 27. Atopic dermatitis Anti-inflammatory, analgetic, regenerative effect, infiltrate resorption, shortening of treatment period , epithelization of ulcer defects 26. Trophic ulcer Anti-inflammatory, analgetic, regenerative effect, infiltrate resorption, shortening of treatment period, decrease in the number of recurrences 25. Psoriasis
  • 29. Infectious and Parasitic diseases Stabilization during pulmonary tuberculosis, decrease in occurrence of postsurgical complications 32. Pulmonary tuberculosis, including chlamidia and mycoplasmal infections Improvement of contractile function characteristics and gallbladder volume characteristics, disappearance of opisthorhid eggs in bile 31. Chronic opisthorchiasis Morbidity reduction in 2 times, disease behavior in a lighter form, decrease in the morbidity period, absence of complications of acute respiratory virus infections 35. Acute respiratory virus infections – prevention and treatment Faster recovery 34. Viral hepatitis Motion activity increase, decrease in intensity of headaches and arthralgia, sleep normalization, decrease in fever period, weakness and sweating, increase of antibody titer to antigens of tick-borne encephalitis and tick-borreliosis 33. Tick-borne encephalitis and tick-borreliosis
  • 30. Cardiology reduction of cardialgia episodes, improvement of life quality, normalization of hemostasis system indexes 38. Noncoronary myocardial traumas (mitral valve prolapse, cardiomyopathy, myocarditis) Hypertensive effect, decrease in resistance of peripheric vessels, improvement of arterial brain circulation indicators, decrease or disappearance of passive congestion signs, catecholamines excretion normalization 37. Alternative hypertension, including hypertonic crisises Evident antianginal effect, decrease in the number of episodes of painless myocardial ischemia, improvement of diastolic function of left ventricle, decrease in the number of stenocardia attacks, decrease of arrhythmia episodes, decrease in the dose of nitroglycerin, normalization of activity level of antithrombin III and erythrocyte deformability 36. Ischemic heart disease: exertional angina, instable angina, myocardial infarction, arrhythmia
  • 31. Pulmonology Normalization of roentgenogram indexes, immunograms and outer breath function, reduction of acerbations and relapses frequency 42. Lung and intrachest lymph nodes sarcoidosis Reduction of bronchoobstruction syndrome 41. Chronic obstructive bronchitis Anti-inflammatory effect 40. Chronic neobstructive bronchitis Decrease in cough and dyspnea, decrease in the need of inhalation bronchial spasmolytic, improvement in bronchial secretion discharge, decrease in the number of rales, external respiration function normalization, immunomodulative effect 39. Bronchial asthma Effectiveness increase and shortening of treatment periods, prevention of lingering illness process 38. Pneumonia
  • 32. Stomatology Evident anti-inflammatory effect 44. Gingivitis Evident anti-inflammatory effect, regeneration stimulation, local blood circulation normalization in paradonta 43. Paradontitis Evident anti-inflammatory effect 42. Adentia and dental prosthesis application
  • 33. Oncology Activation of organism antioxidative protection, suppression of free radical oxidation and normalization of proinflammatory cytokines level 49. Lymphomas (lymphogranulomathosis no Hodgkin’s lymphomas) Decease in node size 48. Uterus fibromyoma Normalization of secretion of sex hormones and immune status 47. Benign tumors of ovarian Prevention of malignant degeneration, anti-inflammatory effect 46. Benign tumors of mammary glands Decrease in the number and intensity of polychemotherapy complications, decrease in the number of recurrences and metastases, pain relief effect 45. Malignant neoplasms (cancer of large and rectum intestine, skin melanoma, stomach cancer, mammary tumor, lung cancer, ovarian cancer, and others)
  • 34. Endocrinology Regression of complications, diabetes course stabilization, decrease in insulin dosage 51. Diabetes and its complications (micro- and macro- anginophathy, hepatosis, cataract, nephropathy, cardiopathy) Disappearance or rapid decrease of solitary noduls 50. Nodular goiter Decrease in the size of thyroid gland, change in its consistency 49 . Diffuse toxic goiter
  • 35. Andrology Spermatogenesis stimulation 55. Secretio-toxic sterility Reduction of pain and dysuric syndromes, sexual function improvement 54. Chronic prostatitis Increase in sexual desire, sexual function improvement 53. Benign hyperplasia of prostate gland Increase in sexual desire, sexual function improvement 52. Andropausal disorders
  • 36. Eye diseases Rise of visual acuity, visual spreading, improvement of microcirculation in bulbar conjunctive 58. Degenerative retina and visual nerve diseases Itch termination, anti-allergenic effect 57. Eye inflammation diseases, including allergenic genesis Improvement of electrocullogram indicators, disappearance of unpleasant feeling in the eye 56. Diabetic retinopathy
  • 37. Liver diseases Normalization of biochemical indicators, size and structure of liver 61. Toxic affection of liver Normalization of biochemical indicators, size and structure of liver 60. Hepatosis Normalization of biochemical indicators, size and structure of liver 59. Chronic hepatitis Normalization of biochemical indicators, size and structure of liver 58. Cirrhosis
  • 38. Vessel diseases Elimination of pain syndrome , faster healing of trophic ulcer 65. Post-thrombophlebitic syndrome Normalization of peripheral circulation and microcirculation 64. Raynaud’s disease Elimination of pain syndrome, decrease of intermittent claudication 63. Obliterating endarteritis Elimination of pain syndrome, decrease of intermittent claudication 62. Obliterating atherosclerosis of arteries of lower limbs
  • 39. Narcology Positive impact on psycho, emotional, and somatic spheres 67. Toxicomania Decrease in internal stress, anxiety, alcohol desire 66. Chronic alcoholism
  • 40. Mechanisms of EHF Action After analyzing information from literary sources, we can list the following mechanisms of EHF action on human body:
  • 41. Normalization of immune system functioning (increased number of T- and decreased number of B-lymphocytes and immunoglobulins (Ig) A and M (Bakaliuk et al., 1998), increased number of T-lymphocytes in comparison with baseline (Kuz’menko, 1998), the concentration of circulating immune complexes, B-lymphocytes and immunoglobulin G decreased and the number of T-lymphocytes and IgA increased (Shliapak et al., 1996), the decrease of CD8+ positive T-lymphocytes (Jin Z, Lin M, Xia J, Zhuang J, Yang R, Li X, et al., 2001), normalization of prior existing disimunnoglobulinea and normalization of functional activity of neutrophiles (Briskin B.C. and et al, 2003), rehabilitation of functional activity of B-lymphocytes and phagocytic activity of neutrophiles (Bukatko B.N., 2003)
  • 42. Increase of nonspecific body resistance (Tumanyac E.E., Termuryanc N.A., 1997); Normalization of lipidic metabolism indicators (increased concentration of high-density lipoproteins, decrease of triglycerides (Kuz’menko, 1998)); Normalization of pro- and anti-oxidant systems ratio (Tumanyac E.E., Temuryanc N.A., 1997); Activation of cell regeneration (increase in proliferation of fibroblasts (Polyakova A.G. et al., 1999))
  • 43. Normalization of the bioelectric brain activity (stabilization of α-rhythm) and disappearance of the pathologically slow δ-waves monitored by means of electroencephalography (Tyshkevich et al., 1998), increase in spectral facility of electroencephalogram α -rhyme (Gubarec M.Y., 1989), and rehabilitation of initially disturbed interzonal and interhemispheric interrelations of basic electroencephalogram rhymes (Stolbikov A. E. and et al, 1991)
  • 44. Activation of hemopoesis in red bone marrow (Lebedeva N.N., Kotrovskaya T.I., 2002); Normalization of rheological blood properties (lowering of blood viscosity, increase of erythrocytes deformation (Parshina S.S. and et al, 2003)); Normalization of coagulant and anticoagulative factors balance (normalization of antithrombin III level (Lopatina N.A. and et al, 2003), normalization of fibrinolitic activity and thrombocyte hemostasis (Bukatko V. N., 2003))
  • 45. Normalization of vessel tone and microcirculation activation (normalization of endothelium vessel reactivity (Parshina S.S. and et al, 2003), normalization of rheogram indicators (Dikke G.B., 1999; Afanaseva T.N., Petrova V.D., 1995) and rheoencephalogramm indicators (Tcarev A.A., Kudinova M.A., 1997)); Normalization of vegetative regulation, stabilization of sympathetic and parasympathetic parts ratio of vegetative nervous system (Dikke G.B., 1999)
  • 46. Normalization of kateholomin and sexual hormones secretion (Tcarev A.A., Kudinova M.A., 1997; Zaporozhan V.N. et al., 1997); Influence on endogenous opioid system (Radzievsky et al., 2001), activation of antinociceptive system (Kirova B.N., 2000); Antistress action – suppression of excessive activity of symphato-adrenal system and activation of stress-limiting systems (Chuyan E.N., Temuryanc N.A., 2005)
  • 47. Suppression of influenza virus reproduction inside the cells and viricidic effect (Podchernyaeva R.Y. et al., 2004); Rehabilitation of mononuclear ability to secret γ -interferon, which enables the decrease in possibility of cancer development for risk group patients ( Sitko S.P. et al., 1993 ); Cytoprotective action towards red marrow cells and liver during polychemotherapy (Karaeva N.P. et al., 2006)
  • 48. Change in structure-dynamic characteristics of cell membranes (Semina I.G. et al., 2007); Anti-inflammatory effect, based on stimulation of mast cell degrannulation and measurement of phagocytes’ functional activity in the center of inflammation (Gapeev A.B, Chemeris N.K., 2007); Inhibition of skin, liver, and brain aging processes (Rodshtat I.V., 2007)
  • 49. Clinical approbation has shown, that the given EHF-therapy is especially effective in cases of medicinal intolerance, presence of contra-indications to methods of traditional physio- and reflexotherapies, as well as insufficient efficiency of the mentioned ways of treatment. The use of EHF-therapy normalizing psychoemotional and regulatory processes in organism , allows to optimize rehabilitation of patients with acute and chronic diseases of various organs and organ systems .
  • 50. It allowed to reject in the given owner’s manual the usual description of medical techniques as «concrete illness – a therapy technique» using principle of initial restoration regulatory processes with subsequent use of «therapy techniques of organ or organ system illness».
  • 51.
    • Possible variants of EHF-therapy use :
    • pathologic focus
    • affected organ projections
    • biologically active points (BAP) and zones
    • big blood vessels projection
  • 52. F rontal view Pulmonary abnormalities Gastritis Liver disorders Gallbladder diseases Fine bowels disorders Large bowels disorders Renal abnormalities Changes in hip joint Changes in knee joint Urinary bladder diseases Stenocardic syndrome Heart failure Heart ischemia Spleen diseases Pancreas abnormalities Prostata gland and urinary bladder diseases Sigmoid colon abnormalities Sexual disorders Maldigestion Diseases in sexual sphere Visual acuity loss Stomach diseases Biologically active zones
  • 53. Biologically active zones Rear view Cervicalpart of spinal cord osteochondrosis Heart abnormalities Spleen diseases Gastric ulcer Pancreas abnormalities Stomach diseases Large bowels disorders Renal abnormalities Sexual disorders Changes in hip joint Ureter abnormalities Urinary bladder diseases Gallbladder diseases Bile duct diseases Pulmonary abnormalities Liver disorders Adrenal gland diseases Fine bowels disorders Diseases of organs of small pelvis
  • 54. All CEM ® science news see www.cem-tech.ru THANK YOU FOR ATTENTION!